Zura Bio Limited (ZURA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zura Bio Limited (ZURA) trades at $5.38 with AI Score 52/100 (Grade B). Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative therapies for immune and inflammatory disorders. Market cap: $511M, Sector: Healthcare.
Price as of Jul 27, 2026 · Last analyzed: May 10, 2026ZURA stock analysis for 2026: Analysts have set a consensus price target of $15.00 for Zura Bio Limited, suggesting 178.8% upside from the current price of $5.38. The AI MoonshotScore is 52/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ZURA: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Zura Bio Limited (ZURA) Healthcare & Pipeline Overview
Zura Bio Limited specializes in developing groundbreaking treatments for immune and inflammatory disorders, leveraging its clinical-stage pipeline that includes ZB-168 and Torudokimab to target critical biological pathways.
What Is the Investment Thesis for ZURA?
Zura Bio Limited presents a compelling investment thesis based on its focused pipeline of innovative therapies for immune and inflammatory disorders. The company’s lead candidate, Torudokimab, is currently in Phase 2 trials, which could provide pivotal data to attract future partnerships or funding. Additionally, ZB-168's unique mechanism of action targeting IL7Rα positions it well in a market projected to grow significantly as demand for effective treatments rises. With a current market capitalization of $511M and no dividend yield, Zura Bio is in a phase of reinvestment and growth, aiming to capitalize on the increasing prevalence of immune disorders. The biotechnology sector is experiencing robust growth, driven by advancements in personalized medicine and biologics, which Zura Bio is strategically positioned to leverage. However, investors should remain aware of the inherent risks associated with clinical-stage companies, including regulatory hurdles and the uncertainties of clinical trial outcomes.
Based on FMP financials and quantitative analysis
ZURA Key Highlights
- Market capitalization of $511M reflects the company's growth potential in the biotech sector.
- Currently in Phase 2 clinical trials for Torudokimab, targeting IL33, a significant step towards commercialization.
- Beta of 0.24 indicates lower volatility compared to the broader market, suggesting stability in stock performance.
- Focus on immune and inflammatory disorders aligns with increasing market demand for innovative therapies.
- No dividend yield, indicating a reinvestment strategy aimed at accelerating growth and development.
Who Are ZURA's Competitors?
ZURA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABBV AbbVie Inc. | $265.08 | +3.18% | $468B | 80 |
| REGN Regeneron Pharmaceuticals, Inc. | $667.17 | +1.70% | $68.7B | 92 |
| AMGN Amgen Inc. | $376.26 | +0.06% | $204B | 84 |
| VRTX Vertex Pharmaceuticals Incorporated | $479.00 | +0.34% | $122B | 98 |
| GILD Gilead Sciences, Inc. | $133.81 | +2.52% | $166B | 94 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| ZVRA Zevra Therapeutics, Inc. | $9.71 | +1.94% | $574M | 69 |
| CRMD CorMedix Inc. | $7.69 | -2.29% | $603M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZURA's Key Strengths?
- Innovative pipeline targeting critical biological pathways in immune disorders.
- Experienced leadership with a strong background in biotechnology.
- Strategic location in a biotech hub enhances collaboration opportunities.
- Focused approach on unmet medical needs in a growing market.
What Are ZURA's Weaknesses?
- Limited financial resources as a small clinical-stage company.
- Dependence on successful clinical trial outcomes for future growth.
- Small team size may limit operational capacity and scalability.
- No current revenue stream, relying on future product approvals.
What Could Drive ZURA Stock Higher?
- Phase 2 clinical trial results for Torudokimab expected in Q3 2026, which could validate the drug's efficacy.
- Development of ZB-168 continues, with preclinical studies indicating promising results.
- Potential partnership discussions with larger pharmaceutical companies to enhance funding and development capabilities.
- Engagement with regulatory bodies to ensure compliance and expedite the approval process for its drug candidates.
- Presentation of clinical data at major biotechnology conferences to attract investor interest and partnerships.
What Are the Key Risks for ZURA?
- Negative return on equity (-54.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial outcomes may not meet expectations, impacting future development.
- Regulatory hurdles could delay the approval process for drug candidates.
- Competition from established companies could limit market share for Zura's products.
- Financial constraints may hinder operational capabilities and research advancement.
What Are the Growth Opportunities for ZURA?
- Growth opportunity 1: The global market for immune and inflammatory disorder therapies is projected to reach $150 billion by 2027, driven by rising incidences of autoimmune diseases. Zura Bio's innovative pipeline, particularly ZB-168, targets critical pathways, giving it a competitive edge in this growing market.
- Growth opportunity 2: The increasing focus on biologics and monoclonal antibodies in treatment regimens presents a significant opportunity for Zura Bio. As healthcare providers shift towards these advanced therapies, Zura's development of Torudokimab positions it to capture market share in a sector expected to grow at a CAGR of 8.5% over the next five years.
- Growth opportunity 3: Collaborations with larger pharmaceutical companies could enhance Zura Bio's research capabilities and accelerate the development of its pipeline. Strategic partnerships could provide funding and resources, enabling faster progression through clinical trials and potentially leading to lucrative licensing agreements.
- Growth opportunity 4: The ongoing advancements in precision medicine create opportunities for Zura Bio to tailor its therapies to specific patient populations, enhancing treatment efficacy. This trend is expected to drive demand for targeted therapies, potentially increasing Zura's market penetration.
- Growth opportunity 5: As regulatory pathways for expedited approvals become more favorable, Zura Bio could benefit from faster time-to-market for its therapies. The FDA's emphasis on innovative treatment options for serious conditions could facilitate quicker access to the market for Zura's promising candidates.
What Opportunities Does ZURA Have?
- Expanding market for immune and inflammatory disorder therapies.
- Potential collaborations with larger pharmaceutical companies.
- Increasing demand for biologics and targeted therapies.
- Favorable regulatory environment for expedited drug approvals.
What Threats Does ZURA Face?
- Intense competition from established biotechnology firms.
- Regulatory challenges and uncertainties in clinical trial outcomes.
- Market volatility impacting funding and investment opportunities.
- Potential for market rejection of new therapies despite clinical success.
What Are ZURA's Competitive Advantages?
- Strong focus on unique biological pathways that differentiate its drug candidates.
- Experienced leadership team with a track record in biotechnology development.
- Strategic location in San Diego, a biotech innovation hub, facilitating collaborations.
- Potential for intellectual property protection enhancing competitive advantage.
- Commitment to addressing unmet medical needs in a growing market.
What Does ZURA Do?
Founded in San Diego, California, Zura Bio Limited is a clinical-stage biotechnology company dedicated to the development of novel medicines aimed at treating immune and inflammatory disorders. The company has made significant strides in its research and development efforts, focusing on two primary candidates: ZB-168, an anti IL7Rα inhibitor that targets diseases driven by the IL7 and TSLP biological pathways, and Torudokimab, a monoclonal antibody that neutralizes IL33, currently in Phase 2 clinical trials. Zura Bio's commitment to addressing unmet medical needs in the immune and inflammatory disorder space positions it as a key player in the biotechnology sector. With a small but dedicated team of 30 employees, the company is well-placed to innovate within this niche market. As it progresses through clinical trials, Zura Bio's strategic focus on developing effective therapies may lead to significant advancements in treatment options for patients suffering from these debilitating conditions. The company’s location in San Diego, a hub for biotech innovation, further enhances its potential for collaboration and growth within the industry.
What Products and Services Does ZURA Offer?
- Develop novel medicines for immune and inflammatory disorders.
- Focus on clinical-stage drug development with an emphasis on innovative therapies.
- Conduct research on biological pathways related to immune response.
- Advance pipeline candidates through clinical trials towards regulatory approval.
- Collaborate with academic and industry partners to enhance research capabilities.
- Aim to address significant unmet medical needs in the healthcare sector.
How Does ZURA Make Money?
- Generate revenue through partnerships and licensing agreements upon successful drug development.
- Focus on clinical trials to validate the efficacy and safety of its drug candidates.
- Leverage intellectual property to protect innovations and attract investment.
- Potential future revenue streams from the commercialization of approved therapies.
- Engage in research collaborations to fund ongoing development efforts.
What Industry Does ZURA Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in genetic research, personalized medicine, and the increasing prevalence of chronic diseases. The global biotechnology market is expected to reach approximately $2.4 trillion by 2028, with significant investments flowing into clinical-stage companies like Zura Bio Limited. As the demand for innovative therapies rises, competition intensifies, particularly in the immune and inflammatory disorder sectors. Zura Bio's focus on unique biological pathways positions it favorably against established players, allowing it to carve out a niche in a highly competitive landscape.
Who Are ZURA's Key Customers?
- Pharmaceutical companies seeking innovative drug candidates for collaboration.
- Healthcare providers looking for effective treatments for patients with immune disorders.
- Investors interested in biotechnology growth opportunities.
- Research institutions collaborating on drug development and clinical trials.
- Patients suffering from immune and inflammatory disorders seeking new treatment options.
FY2026 estForward Outlook
Wall Street analysts project Zura Bio Limited revenue of about $8.3M for fiscal 2026, with EPS near $-0.78. The estimate reflects 7 contributing analysts.
F-Score 2/9Financial Health
Zura Bio Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 15.89 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -55%Key Financial Metrics
Return on equity for Zura Bio Limited stands at -54.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.7%, the inverse of the P/E and a quick read on earnings relative to price.
Zura Bio Limited (ZURA) Valuation Context
Valued at $511M, ZURA is classified as a small-cap stock. Relative to its peer group, ZURA's quantitative score of 52/100 is below the peer average of 90/100.
Company Profile
Zura Bio Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO Sandeep C. Kulkarni. ZURA has traded publicly since 2023.
ZURA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests that executives have confidence in the company's future prospects, which can be a strong signal for investors.
- Positive community sentiment has emerged around Zura Bio's innovative approaches in the biotech sector, attracting attention from both retail and institutional investors.
- Developments in clinical trials have generated excitement, indicating potential breakthroughs that could enhance the company's valuation and market position.
- Social media discussions have shifted towards optimism, with many investors highlighting the company's unique technology as a game changer in its field.
Bear Case
- Concerns about the competitive landscape in the biotech industry have surfaced, with analysts noting that Zura Bio faces significant challenges from established players.
- Recent earnings reports have shown slower-than-expected progress, leading to skepticism about the company's ability to meet growth expectations in the near term.
- Community sentiment has also highlighted apprehension regarding regulatory hurdles that could delay product launches and impact timelines.
- Some investors express caution due to the company's reliance on a few key products, raising concerns about long-term sustainability and market diversification.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
ZURA Latest News
ZURA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZURA.
Price Targets
Consensus target: $15.00
ZURA MoonshotScore
What does this score mean?
The MoonshotScore rates ZURA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest Zura Bio Limited Analysis
Leadership: Sandeep C. Kulkarni
CEO
Sandeep C. Kulkarni has extensive experience in the biotechnology sector, having held various leadership roles in drug development and commercialization. He holds a degree in Molecular Biology and has a strong background in clinical research and strategic management. Prior to joining Zura Bio, he was involved in several successful biotech startups, contributing to their growth and development.
Track Record: Under Sandeep's leadership, Zura Bio has advanced its pipeline candidates into clinical trials, demonstrating significant progress in drug development. His strategic vision has positioned the company to capitalize on emerging opportunities in the biotechnology landscape.
ZURA Healthcare Stock FAQ
What does the AI Score mean for ZURA?
ZURA holds an AI Score of 52/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative therapies for immune and inflammatory disorders. With a promising pipeline including ZB-168 …
What does Zura Bio Limited do?
Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative therapies for immune and inflammatory disorders. The company’s primary candidates include ZB-168, an anti IL7Rα inhibitor, and Torudokimab, a monoclonal antibody targeting IL33, which is currently in Phase 2 clinical trials. Zura Bio aims to address significant unmet medical needs in these therapeutic areas.
What do analysts say about ZURA stock?
Analysts view Zura Bio Limited as a promising player in the biotechnology sector, particularly due to its focused pipeline and innovative approach to treating immune disorders. Key valuation metrics indicate a market cap of $511M, with potential for growth as clinical trials progress. Analysts highlight the importance of upcoming trial results for Torudokimab as a critical factor influencing future stock performance.
What are the main risks for ZURA?
Zura Bio Limited faces several risks inherent to clinical-stage biotechnology companies. These include the potential for unfavorable clinical trial results, which could significantly impact the company’s future growth and funding prospects. Additionally, regulatory challenges may arise during the approval process, and competition from established firms could limit market opportunities for Zura's innovative therapies.
What are the key factors to evaluate for ZURA?
Zura Bio Limited (ZURA) holds an AI score of 52/100 (moderate). Analysts target $15.00 (+179%). Not financial advice.
How frequently does ZURA data refresh on this page?
ZURA's price was last updated on Jul 27, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZURA's recent stock price performance?
Zura Bio Limited (ZURA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting critical biological pathways in immune disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZURA overvalued or undervalued right now?
Zura Bio Limited (ZURA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $15.00 (+179%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZURA before investing?
Before investing in Zura Bio Limited (ZURA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and subject to change as new information becomes available.